These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11166875)

  • 1. Product development plan for new vaccine technologies.
    Ellis RW
    Vaccine; 2001 Feb; 19(13-14):1559-66. PubMed ID: 11166875
    [No Abstract]   [Full Text] [Related]  

  • 2. Licensing IP to ensure accessibility to vaccines and other immunisation-related products.
    Mehta JM
    Vaccine; 2001 Feb; 19(13-14):1581-7; discussion 1592-3. PubMed ID: 11166878
    [No Abstract]   [Full Text] [Related]  

  • 3. WHO expectation and industry goals.
    Vandersmissen W
    Vaccine; 2001 Feb; 19(13-14):1611-5. PubMed ID: 11166883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic trends in the vaccine market.
    Kresse H; Shah M
    Nat Rev Drug Discov; 2010 Dec; 9(12):913-4. PubMed ID: 21119727
    [No Abstract]   [Full Text] [Related]  

  • 5. [Relationship between pharmaceutical industry and public health in vaccination].
    Gervasi G; Capanna A; Soncini R; Zaratti L; Franco E
    Ig Sanita Pubbl; 2015; 71(2):225-32. PubMed ID: 26057178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key drivers behind the development of global vaccine market.
    Gréco M
    Vaccine; 2001 Feb; 19(13-14):1606-10. PubMed ID: 11166882
    [No Abstract]   [Full Text] [Related]  

  • 7. Carole Ho.
    Nat Rev Drug Discov; 2016 Nov; 15(12):816. PubMed ID: 27895326
    [No Abstract]   [Full Text] [Related]  

  • 8. The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success.
    Evens RP; Kaitin KI
    Clin Pharmacol Ther; 2014 May; 95(5):528-32. PubMed ID: 24448474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicine. The intangible value of vaccination.
    Rappuoli R; Miller HI; Falkow S
    Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
    [No Abstract]   [Full Text] [Related]  

  • 10. Delivering vaccines into the skin without needles and syringes.
    Partidos CD
    Expert Rev Vaccines; 2003 Dec; 2(6):753-61. PubMed ID: 14711359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth of the Asian health-care market: global implications for the pharmaceutical industry.
    Epstein RJ
    Nat Rev Drug Discov; 2007 Oct; 6(10):785-92. PubMed ID: 17853900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases.
    Kirchheimer B
    Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833
    [No Abstract]   [Full Text] [Related]  

  • 15. [Criteria for introducing new vaccines into the vaccination calendar].
    Ramírez Fernández R; Gutiérrez Rodríguez MA; Sanz Moreno JC
    Rev Esp Quimioter; 2007 Mar; 20(1):131-42. PubMed ID: 17530047
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccines for the developing world: current status and future directions.
    Wenger J
    Vaccine; 2001 Feb; 19(13-14):1588-91. PubMed ID: 11166879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bad medicine.
    Sheridan C
    Nat Biotechnol; 2007 Jul; 25(7):707-9. PubMed ID: 17621284
    [No Abstract]   [Full Text] [Related]  

  • 18. Technologies that make administration of vaccines safer.
    Clements CJ; Larsen G; Jodar L
    Vaccine; 2004 May; 22(15-16):2054-8. PubMed ID: 15121322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US advisory panel urges government to subsidise vaccine costs. Recommendations would increase vaccination rates and stimulate research and development.
    Ault A
    Lancet; 2003 Aug; 362(9383):539. PubMed ID: 12932398
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccine candidates for poor nations are going to waste.
    Kaslow DC; Black S; Bloom DE; Datla M; Salisbury D; Rappuoli R
    Nature; 2018 Dec; 564(7736):337-339. PubMed ID: 30560957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.